Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMB216P
- Development stage
- Preclinical
- Lead developer
- ImmunoBiochem
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Administration
- Subcutaneous
01
Overview
IMB216P is a first-in-class degrader-antibody conjugate (DAC) developed by ImmunoBiochem for the treatment of chronic autoimmune and inflammatory diseases. It consists of a monoclonal antibody targeting the interleukin-7 receptor alpha (IL7RA/CD127) conjugated to a proteolysis-targeting chimera (PROTAC) payload that induces the degradation of Janus kinase 1 (JAK1) and Tyrosine kinase 2 (TYK2). By targeting IL7RA, IMB216P selectively delivers the degrader to pathogenic T cells while sparing regulatory T cells (Tregs), which typically express low levels of CD127. This targeted approach aims to provide potent immunosuppression with improved safety compared to systemic JAK inhibitors. The drug is currently in IND-enabling studies for indications including inflammatory bowel disease (IBD), psoriasis, and systemic lupus erythematosus.
- Other names
- IMB216PIMB-216PIMB 216P
02
Targets
TYK2 (Tyrosine kinase 2)JAK1 (Janus kinase 1)
Beyond the preview
Go deeper on IMB216P.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMB216P.